KLI

검색

Ulsan Univ. Repository

Browsing by 저자 : Sang-We Kim

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

가 나 다 라 마 바 사 아 자 차 카 타 파 하

또는 첫 단어:

정렬 기준:
정렬:
결과 수
저자 수

전체 결과 23건 중 1-23 번을 표시중입니다.

1 Article A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors Byoung Chul Cho ; Ji-Youn Han ; Sang-We Kim ; et al 2022
2 Article A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data Parneet Cheema ; Byoung Chul Cho ; Helano Freitas ; et al 2023
3 Article Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions Caicun Zhou ; Ke-Jing Tang ; Byoung Chul Cho ; et al 2023
4 Article Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial Byoung Chul Cho ; Dong-Wan Kim ; Alexander I Spira ; et al 2023
5 Article CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report Dong-Wan Kim ; Sang-We Kim ; D Ross Camidge ; et al 2023
6 Article Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis Sora Kang ; Hyehyun Jeong ; Ji Eun Park ; et al 2023
7 Article Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study Melissa L Johnson ; Byoung Chul Cho ; Alexander Luft ; et al 2023
8 Article Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis Byoung Chul Cho ; Dong-Wan Kim ; Ullas Batra ; et al 2023
9 Article Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer Pasi A Jänne ; Christina Baik ; Wu-Chou Su ; et al 2022
10 Article Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy Jaewon Hyung ; Hyunseok Yoon ; Chang-Min Choi ; et al 2023
11 Article Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations Alessandra Bearz ; Jean-François Martini ; Jacek Jassem ; et al 2023
12 Article First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial Sang-We Kim ; Adam Pluzanski ; Alain Vergnenegre ; et al 2022
13 Article Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial Margarita Majem ; Jonathan W Goldman ; Thomas John ; et al 2022
14 Article Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment Myeong Geun Choi ; Chang-Min Choi ; Dae Ho Lee ; et al 2022
15 Article Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer Changhwan Sung ; Jinhyeon An ; Soohyeon Lee ; et al 2023
16 Article Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer Shinkyo Yoon ; Hannah Yang ; Hyun-Min Ryu ; et al 2022
17 Article Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment Yoon Jung Jang ; Dong-Gon Hyun ; Wonjun Ji ; et al 2023
18 Article Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON) Edward B Garon ; Byoung Chul Cho ; Alexander Luft ; et al 2023
19 Article Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC Sang-We Kim ; Kye Young Lee ; Ajlan Atasoy ; et al 2022
20 Article Prognostic value of MRI volumetric parameters in non-small cell lung cancer patients after immune checkpoint inhibitor therapy: comparison with response assessment criteria Yun Hwa Roh ; Ji Eun Park ; Sora Kang ; et al 2023
21 Article Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817 Luis G Paz-Ares ; Tudor-Eliade Ciuleanu ; Adam Pluzanski ; et al 2023
22 Article Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1 Martin Reck ; Tudor-Eliade Ciuleanu ; Jong-Seok Lee ; et al 2023
23 Article The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study Jwa Hoon Kim ; Seyoung Seo ; Jee Hyun Kim ; et al 2022

OAK Ulsan Univ. Repository는 국립중앙도서관 OAK Repository 보급사업으로 구축되었습니다.